Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;57(4):1596-602.
doi: 10.1128/AAC.01334-12. Epub 2013 Jan 14.

N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam

Affiliations

N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam

Marion J Skalweit et al. Antimicrob Agents Chemother. 2013 Apr.

Abstract

Class C cephalosporinases are a growing threat, and clinical inhibitors of these enzymes are currently unavailable. Previous studies have explored the role of Asn152 in the Escherichia coli AmpC and P99 enzymes and have suggested that interactions between C-6' or C-7' substituents on penicillins or cephalosporins and Asn152 are important in determining substrate specificity and enzymatic stability. We sought to characterize the role of Asn152 in the clinically important CMY-2 cephalosporinase with substrates and inhibitors. Mutagenesis of CMY-2 at position 152 yields functional mutants (N152G, -S, and -T) that exhibit improved penicillinase activity and retain cephamycinase activity. We also tested whether the position 152 substitutions would affect the inactivation kinetics of tazobactam, a class A β-lactamase inhibitor with in vitro activity against CMY-2. Using standard assays, we showed that the N152G, -S, and -T variants possessed increased catalytic activity against cefoxitin compared to the wild type. The 50% inhibitory concentration (IC50) for tazobactam improved dramatically, with an 18-fold reduction for the N152S mutant due to higher rates of enzyme inactivation. Modeling studies have shown active-site expansion due to interactions between Y150 and S152 in the apoenzyme and the Michaelis-Menten complex with tazobactam. Substitutions at N152 might become clinically important as new class C β-lactamase inhibitors are developed.

PubMed Disclaimer

Figures

Fig 1
Fig 1
(a) Molecular model of CMY-2 (atoms colored by type) superimposed on the N152S variant (orange) and the N152S CMY-2:tazobactam Michaelis-Menten complex (yellow, shown without tazobactam), demonstrating a decrease from the N152-O-δ–Y150-OH distance (5.2 Å) to the S152-O-γ–Y150-OH distance (3.9 Å), enlarging the active site to accommodate R1 side chains. In the Michaelis-Menten complex, this distance decreases further to 3.5 Å. The distance between the catalytic serine at position 64 and Tyr150, thought to be the general base that activates the serine OH for attack on the β-lactam carbonyl, does not vary in these constructs. (b) Michaelis-Menten complex of tazobactam with the N152S CMY-2 variant, with the inhibitor carbonyl moiety in the oxyanion hole formed by the backbone nitrogens of S64 and S318. The S152-O-γ–Y150-OH distance is decreased further to 3.5 Å, from 4 Å, when tazobactam is docked in the active site.

Similar articles

Cited by

References

    1. Jacoby GA. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161–182 - PMC - PubMed
    1. Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, Pérez JL, Oliver A. 2007. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob. Agents Chemother. 51:4329–4335 - PMC - PubMed
    1. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. 1999. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43:424–427 - PMC - PubMed
    1. Livermore DM. 1992. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2046–2048 - PMC - PubMed
    1. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633–1641 - PMC - PubMed

Publication types

MeSH terms